| 摘要 |
The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug hypersensitivity syndrome (HSS). It was discovered that an HLA-13 allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA - B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all t he patients tested have the HLA-13*1502 allele. In addition, another HLA-13 allele, HLA-B*5801, is particularly associated with SJS/TEN or HSS induced b y allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythem a multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-13*4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphis m markers) located between the DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. |
